<DOC>
	<DOCNO>NCT02647112</DOCNO>
	<brief_summary>Clinical trial determine performance characteristic ( sensitivity specificity ) Bladder EpiCheck test compare gold standard cystoscopy pathology .</brief_summary>
	<brief_title>Utility Bladder EpiCheck Detection Recurrent Urothelial Carcinoma</brief_title>
	<detailed_description>Clinical trial determine performance characteristic ( sensitivity specificity ) Bladder EpiCheck test compare gold standard cystoscopy pathology patient monitor reccurrence bladder cancer .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Patient diagnose incident recurrent urothelial cell carcinoma undergo surveillance monitoring urothelial cell carcinoma Has urothelial cell carcinoma tumor resect within past 12 month Has plan cystoscopic surveillance Planning undergo radical cystectomy chemotherapyradiation UCC</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Urine</keyword>
	<keyword>Methylation</keyword>
</DOC>